Diabetic Retinopathy
Diabetic retinopathy is a leading cause of vision loss driven by microvascular dysfunction, inflammation, and pathological angiogenesis, making it a key focus in ocular drug development and ocular pharmacology.
However, preclinical diabetic retinopathy models face significant translational challenges, including slow disease onset and incomplete replication of proliferative stages in animals.
These limitations can be addressed through validated in vivo models, multi-species approaches, and quantitative imaging endpoints, enabling more predictive efficacy data and improved clinical translation.
DL-AAA Induced Retinal Neovascularization
The DL-2-aminoadipic acid (AAA) model of RNV in Dutch Belted rabbits is used to evaluate therapeutic efficacy of test articles through quantification of vascular leakage inhibition. Our team of experts has developed this model with consistent results in the Dutch Belted rabbit.
Laser-Induced Choroidal Neovascularization
The experimental laser-induced CNV model was designed to assess the efficacy of test articles for conditions including wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Our team of experts has developed reproducible models with consistent results in mice, rats, and swine.
VEGF-Induced Retinal Leakage and Neovascularization
The VEGF-induced retinal leakage and neovascularization model was designed to assess the efficacy of test articles for the treatment of diabetic retinopathy and wet age-related macular degeneration (wet AMD). Our team of experts has developed this model with consistent results in in the Dutch Belted rabbit.